Photos depict models, not actual patients or healthcare professionals.
*Phenylketonurics: Welchol for Oral Suspension contains 27 mg phenylalanine per 3.75 gram dose. Phenylalanine can be harmful to patients with
phenylketonuria (PKU).
Welchol Tablets may be taken either as:
Because of tablet size, Welchol Tablets should be used with caution in patients with swallowing disorders.
Welchol for Oral Suspension is recommended for, but not limited to, use in any patient who has difficulty swallowing.
Remember, it’s Welchol plus eating right, exercising, and taking your current medications that could help you keep taking steps in the right direction. And take Welchol as prescribed by your healthcare provider.
Print your Welchol Savings Card and start saving today!‡
Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply.‡Restrictions apply based on eligibility.
Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply.‡Restrictions apply based on eligibility.
Welchol, along with diet and exercise, lowers LDL or “bad” cholesterol.
Welchol lowers LDL cholesterol in boys, and in girls who have had a menstrual period, ages 10 to 17 years, with a condition known as heterozygous familial hypercholesterolemia (a genetic disorder that causes high cholesterol).
Welchol, along with diet and exercise, also lowers blood sugar levels in adult patients with type 2 diabetes mellitus.
Welchol should not be used to treat type 1 diabetes or diabetic ketoacidosis.
Welchol has not been shown to prevent heart disease or heart attacks.
Welchol has not been studied with all anti-diabetes medications.
Welchol has not been studied in all types of hypercholesterolemia.
Welchol has not been studied in children younger than 10 years old or in girls who have not had a menstrual period.
To the Patient: You must present this card to the pharmacist along with your WELCHOL® (colesevelam HCl) prescription to participate in the program. For patients with commercial insurance, savings per prescription of WELCHOL will apply after the following out‐of‐pocket expenses are met: $10 per prescription for a 30‐day supply of WELCHOL or $0 per prescription for a 90‐day supply of WELCHOL. Offer may not be combined with any other program offer or discount for WELCHOL. Savings for WELCHOL are subject to a maximum benefit of $150 per 30‐day prescription or $450 per 90‐day prescription. If you have questions regarding your eligibility or benefits, or wish to discontinue participation, call (877) 264‐2440
(8 AM – 8 PM ET, Monday‐Friday). When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if you are enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS; or where taxed, restricted, or prohibited by law; or if you do not otherwise comply with the terms of this card. Further, you agree to discontinue using the card if you enroll in any state or federal health care program during the program period. Offer valid in US and Puerto Rico only.
To the Pharmacist: When you use this card, you are certifying that the patient is not enrolled in any federal, state, or other governmental programs for this prescription.
Cosette Pharmaceuticals, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.
Trademarks not owned by Cosette Pharmaceuticals, Inc., are property of their respective owners.
Welchol is available by prescription only. Ask your HCP if Welchol is right for you.
Welchol is not for everyone, especially those with:
Tell your health care provider (HCP) if you have high triglycerides (greater than 300 mg/dL). High levels of triglycerides in your blood can cause acute pancreatitis (inflammation of the pancreas). Discontinue Welchol and seek prompt medical attention if the symptoms of acute pancreatitis occur.
Welchol should not be taken if you have stomach or intestinal problems, including gastroparesis (when the stomach takes too long to empty its contents), abnormal contractions of the digestive system, a history of major gastrointestinal tract surgery, if you have trouble swallowing, by those who might be at risk for intestinal blockage, or if you have vitamin A, D, E, or K deficiencies. Tell your HCP if you have any of these conditions.
Cases of intestinal blockage have occurred. Discontinue Welchol and seek medical attention if severe abdominal pain or severe constipation occurs.
Welchol has known interactions with cyclosporine, glimepiride, glipizide, glyburide, levothyroxine, certain birth control pills, olmesartan medoxomil, and metformin extended-release (ER). Welchol has not been studied with all combinations of drugs and supplements. Please tell your HCP about all medications and vitamins/supplements you may be taking before beginning Welchol, as your HCP may tell you to take your other medications and vitamins/supplements 4 hours before taking Welchol.
Remember to tell your HCP if you are pregnant, plan to become pregnant, or are breastfeeding.
Welchol (colesevelam HCl) for Oral Suspension should not be taken in its dry form.
Welchol for Oral Suspension is recommended for, but not limited to, use in appropriate pediatric patients, as well as any patient who has difficulty swallowing.
Phenylketonurics: Welchol for Oral Suspension contains 27 mg phenylalanine per 3.75 gram packet. Phenylalanine can be harmful to patients with phenylketonuria (PKU).
In clinical trials, the adverse reactions observed in ≥2% of patients, and more commonly with Welchol than placebo (“sugar pill”), regardless of investigator assessment of causality seen in:
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full Prescribing Information for Welchol® (colesevelam HCl).
To contact us with questions or concerns about a Cosette Pharmaceuticals product,
please call us: 1-800-922-1038
WELCHOL is a registered trademark of Cosette Pharmaceuticals, Inc.
© 2022 Cosette Pharmaceuticals, Inc. CP-US-WC-001 06/22